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Fc gamma receptors are expressed in the
developing rat brain and activate
downstream signaling molecules upon
cross-linking with immune complex
Marianna Stamou1†, Ana Cristina Grodzki1†, Marc van Oostrum2, Bernd Wollscheid2 and Pamela J. Lein1*
Abstract
Background: Exposure of the developing brain to immune mediators, including antibodies, is postulated to increase
risk for neurodevelopmental disorders and neurodegenerative disease. It has been suggested that immunoglobulin G-
immune complexes (IgG-IC) activate Fc gamma receptors (FcγR) expressed on neurons to modify signaling events in
these cells. However, testing this hypothesis is hindered by a paucity of data regarding neuronal FcγR expression and
function.
Methods: FcγR transcript expression in the hippocampus, cortex, and cerebellum of neonatal male and female
rats was investigated ex vivo and in mixed cultures of primary hippocampal and cortical neurons and astrocytes
using quantitative PCR analyses. Expression at the protein level in mixed cultures of primary hippocampal and
cortical neurons and astrocytes was determined by immunocytochemistry, western blotting, proteotype analysis,
and flow cytometry. The functionality of these receptors was assessed by measuring changes in intracellular
calcium levels, Erk phosphorylation, and IgG internalization following stimulation with IgG-immune complexes.
Results: FcgrIa, FcgrIIa, FcgrIIb, FcgrIIIa, and Fcgrt transcripts were detectable in the cortex, hippocampus, and
cerebellum at postnatal days 1 and 7. These transcripts were also present in primary hippocampal and cortical
cell cultures, where their expression was modulated by IFNγ. Expression of FcγRIa, FcγRIIb, and FcγRIIIa, but not
FcγRIIa or FcRn proteins, was confirmed in cultured hippocampal and cortical neurons and astrocytes at the
single cell level. A subpopulation of these cells co-expressed the activating FcγRIa and the inhibitory FcγRIIb.
Functional analyses demonstrated that exposure of hippocampal and cortical cell cultures to IgG-IC increases
intracellular calcium and Erk phosphorylation and triggers FcγR-mediated internalization of IgG.
Conclusions: Our data demonstrate that developing neurons and astrocytes in the hippocampus and the
cortex express signaling competent FcγR. These findings suggest that IgG antibodies may influence normal
neurodevelopment or function via direct interactions with FcγR on non-immune cells in the brain.
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IC), Cross-linking, Neurodevelopment
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Background
Emerging evidence that neurons express classic immune
molecules such as complement receptors and MHC class I
proteins has spurred significant research interest in the role
of immune molecules in CNS development and disease
[1–6]. A class of immune molecules that is receiving in-
creased attention in this context is the Fc gamma receptors
(FcγR) [7–9]. Neuronal FcγR have been shown to contrib-
ute to kainic-acid- and amyloid-β-mediated neurotoxicity
in the brain [10, 11], but have also been suggested to play a
role in normal neurodevelopment [12, 13]. More recently,
neuronal uptake of antibodies against intracellular neur-
onal proteins has been shown to occur in the adult brain
and to be mediated primarily via clathrin-dependent FcγR
endocytosis, with limited microglial involvement, ultim-
ately leading to target protein degradation [14, 15]. IgG
antibodies against viral or self-antigens are often found in
the developing human brain and at least a subset of these
has been linked to increased risk for neurodevelopmental
disorders [16–26]. However, the mechanisms by which im-
munoglobulins interfere with neurodevelopment remain
speculative. Considering that IgG is the cognate ligand for
FcγR, expression of FcγR on neurons and macroglia in the
developing brain might provide a plausible biological
mechanism linking IgG antibodies found in the developing
brain to adverse neurodevelopmental outcomes [27–29].
FcγR are transmembrane glycoproteins expressed on
effector cells of the innate immune system that
recognize the constant Fc (fragment crystallizable) do-
main of immunoglobulin G (IgG) [30, 31]. Cross-
linking of FcγR by IgG immune complexes (IgG-IC)
triggers IgG internalization, cytokine release, phagocyt-
osis, antibody-dependent cytotoxicity, regulation of
antibody production, and gene transcription [32]. The
major FcγR family members are FcγRIa (CD64),
FcγRIIb (CD32), and FcγRIIIa (CD16). “Activating” re-
ceptors FcγRIa and FcγRIIIa signal via an immunore-
ceptor tyrosine-based activation motif (ITAM). Their
cross-linking by IgG-IC increases intracellular calcium,
activates cellular kinases, and triggers transcription of
genes involved in host immune responses. These signals
are attenuated by the “inhibiting” receptor (FcγRIIb),
which carries an immunoreceptor tyrosine-based inhib-
ition motif (ITIM) sequence. Each FcγR has different
affinity for individual IgG isotypes, and the co-
expression of activating and inhibitory FcγR results in a
complex threshold for cellular activation that is
dependent on the relative expression of FcγR subtypes,
their posttranslational modifications, and the IgG iso-
type composition of their IgG-IC ligand [33–35]. An
exception is the neonatal Fc receptor (FcRn). FcRn is an
MHC class I molecule, which is thought to protect IgG
from catabolism through bidirectional transcytosis of
IgG across endothelial and epithelial cells [36].
Microglia, which are the innate immune cells of the
brain, are known to express FcγR, which mediate micro-
glial phagocytosis of dying and stressed cells [37, 38].
However, emerging evidence suggests that cells in the
brain that are not involved in immune surveillance, spe-
cifically, neurons and macroglia, may also express FcγR.
FcgRI, II, III, and IV transcripts have been reported in
mouse cortical and hippocampal neurons and astrocytes
[39]. At the protein level, detection of FcγRI and FcγRII
but not FcγRIII were reported in a recent whole prote-
ome analysis of the adult mouse brain, while FcγRI but
neither FcγRII nor FcγRIII were detected in samples
from DIV10 and DIV15 mouse cortical cells [40]. There
are also reports of FcγR expression in mouse cortical as-
trocytes [40, 41] and FcγRIIb expression on mouse par-
valbumin neurons, Purkinje cells, and Bergman glia [10,
13]. In humans, FcγRIIb expression has been reported in
the hippocampus [42]. However, to date, very few studies
have comprehensively profiled FcγR in the developing
brain or investigated the signaling competence of neur-
onal and macroglial FcγR [43, 44].
The objectives of this study, therefore, were to
characterize expression and cell surface presence of FcγR
in neurons and astrocytes of the developing rat brain and
to assess whether immune complexes added to primary
cultures of neurons and astrocytes trigger activation of
canonical FcγR downstream signaling.
Methods
Experimental design
The in vivo and in vitro experiments were conducted at
the developmental times illustrated in the schematic
below:
Animals
For the majority of studies, which were performed at UC
Davis (Davis, CA), timed pregnant female Sprague Dawley
rats were purchased from Charles River Laboratories and
housed individually in standard plastic cages with Alpha-
Dri bedding (Shepherd Specialty Papers) in a temperature-
controlled room (22 ± 2 °C) on a normal 12 h light/dark
cycle. Food and water were provided ad libitum.
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For the surfaceome analyses, which were performed at
the ETH (Zurich, Switzerland), Sprague Dawley rats were
purchased from Charles River Laboratories and group
housed (three per cage) in Allentown individually venti-
lated cages with Lignocel bedding (JRS - Rettenmaier) in a
temperature-controlled room (21 ± 2 °C) on a normal 12-
h light/dark cycle. Food and water (Kliba) were provided
ad libitum.
Primary neuronal cell culture
Primary cultures of dissociated hippocampal or cortical
cells were prepared and maintained as previously de-
scribed [45]. Briefly, hippocampi and neocortices from
pooled postnatal day 0 (P0) or P1 male and female rat
pups were dissociated and plated onto tissue culture plas-
tic or on glass coverslips precoated with poly-L-lysine
(Sigma), at different densities depending on the endpoint
to be analyzed (detailed information provided in the re-
spective method section). Cells were maintained in Neu-
robasal A media supplemented with B27 and 2 mM
Glutamax (all from Life Technologies), except for cultures
used in the proteomics experiments, for which cells were
maintained in Neural Q supplemented with GS21 (both
from Sigma). Cytosine-D-arabinofuranoside (araC; 5 μM,
Sigma) was added to the medium on day in vitro (DIV) 4
to prevent overgrowth of astrocytes. Half the medium was
replaced with fresh media (without araC) twice weekly.
Rat peritoneal cells
Resident peritoneal macrophages were collected from
adult female Sprague Dawley rats, plated at a density of
2 × 105 cells/cm2 and maintained as described [46].
Cells were plated on tissue culture plastic (Thermo
Fisher Scientific) and allowed to adhere for 1 h at 37 °C
in a 5% CO2 humidified incubator. Non-adherent cells
were removed by washing the plates twice with warm
RPMI 1640 medium (Gibco). This procedure enriches
remaining adherent cells for macrophages (~ 95%) [47].
Using this macrophage-enriched population of periton-
eal cells, specificity of the anti-FcγRI (anti-CD64) and
anti-FcγRII (anti-CD32) antibodies was determined by
confirming lack of CD64/CD32 immunolabeling on
CD3+ cells and positive CD64/CD32 immunolabeling
on CD3- cells.
Quantitative real-time PCR (qPCR)
To assess Fcgr transcript levels in vivo, rat pups were
euthanized on P1 or P7 (n = 3 pups of each sex and age
from the first litter; n = 3 female and 3 male pups at P1
and 3 female and 2 male pups at P7 from the second
litter). Sex was determined by anogenital distance. P1
pups were euthanized by decapitation; P7 pups were
placed on a cloth-lined Petri dish on top of ice to in-
duce hypothermic anesthesia, and then decapitated,
and liver, spleen, and brain were removed for further
analysis. To assess in vitro Fcgr expression, cultured
hippocampal or cortical cells were harvested from P1
male and female pups (n = 6 cultures per experimental
group with 3 cultures each from 2 independent dissec-
tions; cells from both sexes were pooled). Immediately
following euthanasia, the brain (microdissected into
hippocampus, cortex, and cerebellum, after carefully re-
moving meninges), liver, and spleen were harvested and
placed in RNAlater overnight (Life Technologies). The
following day, RNAlater was removed and the samples
stored at − 80 °C until further analysis. To assess in
vitro expression of Fcgr, cell lysates were collected from
hippocampal and cortical neuron-glia co-cultures
(seeded at a density of 0.5–1 × 105 cells/cm2) on DIV 2,
7, 14, and 21. To investigate the effects of IFNγ on Fcgr
transcript expression, cortical cell cultures were ex-
posed to recombinant rat IFNγ (100 ng/ml, Peprotech)
added to the culture medium on DIV 1 for 24 or 48 h
(3 cultures derived from each of 6 independent dissec-
tions were used). Cells were lysed in Buffer RLT
(RNeasy Mini Kit, Qiagen), lysates homogenized using
QIAShredder spin columns (Qiagen), and homogenates
stored at − 80 °C until further processed.
Extraction of total RNA and synthesis of cDNA from
brain tissues or cell cultures were performed as previ-
ously described [48]. cDNA was loaded in duplicate in
MicroAmp Optical 384-well plates (Life Technologies),
and qPCR was performed at the Real-Time PCR Re-
search and Diagnostics Core Facility at UC Davis using
Taqman technology on a 7900HT Fast Real-Time PCR
System (Applied Biosystems). Primer and probe sets,
designed to span an exon-exon junction, were obtained
from Integrated DNA Technologies (IDT). Gene acces-
sion numbers and primer/probe set product number
and amplification efficiencies are presented in Table 1.
Specific amplification of products of the desired
length was verified using gel electrophoresis (not
shown). qPCR results were analyzed using the Applied
Biosystems 7900HT Fast Real-Time PCR System soft-
ware (SDS, Thermo Fisher Scientific; version 2.4) to ob-
tain Ct values [49]. Across all qPCR experiments, each
sample was quantified in duplicate, and duplicate Ct
values were averaged for analysis of results.
Relative differences in gene expression between ex-
perimental groups were calculated as described previ-
ously [48]. Transcript levels were normalized to the
concentration of the reference gene Pgk1 [48, 50], and
relative expression ratios were calculated by the Pfaffl
method [51] using REST 2009 software (Qiagen). Con-
sistent with prior studies demonstrating that Pgk1 is a
stably expressed gene in the brain [50, 52], expression
levels of Pgk1 were not different between experimental
conditions.
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Western blotting
Cortical and hippocampal cell cultures (seeded at a cell
density of 1 × 105 cells/cm2) were lysed in ice-cold lysis
buffer [50 mM Tris, pH 8.0, 150 mM NaCl, 1% Triton
X-100, 0.1% sodium dodecyl sulfate (SDS), 0.5% sodium
deoxycholate, and 1X Halt Protease and Phosphatase
Inhibitor Cocktail (Thermo Fisher Scientific)]. The pro-
tein concentration of cell lysates was determined using
the Pierce BCA Protein Assay Kit (Thermo Fisher
Scientific), and 30 μg of protein from each sample was
separated by SDS PAGE using 10% Bolt Bis-Tris Plus
Gels (Invitrogen), transferred onto PVDF membranes
using the iBlot 2 dry transfer system, and immuno-
blotted using the iBind Western System (Life Technolo-
gies). Proteins were identified based on expected
molecular weight of immunoreactive bands as indicated
in the product information provided by the supplier
from which antibodies were purchased: 40–45 kDa for
FcγR isoforms (FcγRIa: rabbit polyclonal anti-CD64,
Santa Cruz Biotechnology sc-15364, RRID
AB_2103451, 10 μg/ml; FcγRIIIa: rabbit monoclonal
anti-CD16, Abcam ab109223, RRID AB_10863447, di-
lution 0.5 μg/ml), 37 kDa for GAPDH (rabbit monoclo-
nal anti-GAPDH, Cell Signaling Technology 2118,
RRID AB_561053, dilution 1:6000) and 55 kDa for βIII-
tubulin (mouse monoclonal anti-β-III-tubulin, Milli-
pore MAB1637, RRID AB_2210524, dilution 1:6000).
GAPDH (37 kDa) was used as a loading control for the
western blots of FcγRIa (45–50 kDa); βΙΙΙ-tubulin
(55 kDa), for western blots of FcγRIIIa (37 kDa). Since
all tissues express FcγR, and we could not locate an
FcγR knockout mouse, loading buffer was used as a
negative control; lysates of peritoneal macrophages
(30 μg per lane) were used as a positive control. Densi-
tometric analysis was performed using Image Studio
Lite software (RRID SCR_014211), v4.0 (Licor Biotech-
nology). Densitometric values for target proteins were
normalized to densitometric values of loading controls
(GAPDH for FcγRIa and βIII-tubulin for FcγRIIb,
FcγRIIIa, and FcRn) in the same sample. FcγR protein
expression was investigated in 2 cultures from each of
2 independent dissections.
Flow cytometry
Rat cortical cells were dissociated, suspended in
phosphate-buffered saline (PBS) containing 2% fetal
bovine serum (FBS, LifeLine Cell Technology), and di-
vided into flow cytometry tubes (5 ml polystyrene round-
bottom tubes) for labeling, with 5 × 106 cells/ml/tube.
Cells were pelleted by centrifugation at 250×g for 5 min
and re-suspended in primary antibody solutions: anti-
FcγRI (rabbit polyclonal anti-CD64, Santa Cruz Biotech-
nology sc-15364, RRID AB_2103451, 2 μg/ml) and anti-
FcγRII (mouse anti-rat CD32, BD Biosciences 550271,
RRID AB_393568, 2 μg/ml) in PBS with 2% FBS. Cells
were incubated for 40 min at room temperature on an or-
bital shaker. Cells were then centrifuged and washed with
PBS, fixed for 30 min with 2% paraformaldehyde (PFA,
Sigma), and permeabilized with 0.25% Triton X-100
(Fisher Scientific) in PBS for 10 min. After
permeabilization, cells were centrifuged and incubated
with primary antibodies against MAP2b (guinea pig poly-
clonal anti-MAP2b, Synaptic Systems 188,004, RRID
AB_2138181, dilution 1:1000) or GFAP (guinea pig poly-
clonal anti-GFAP, Synaptic Systems 173,004, RRID AB
10641162, dilution 1:1000) in PBS containing 1% bovine
serum albumin (BSA) and 10% goat serum for 1 h at room
temperature. Cells were washed twice by adding PBS to
each tube, shaking vigorously and then centrifuging for
5 min before re-suspending in PBS. Cells were incubated
with fluorescently labeled secondary antibodies in PBS for
45 min at room temperature. Phycoerythrin (PE)-labeled
secondary antibody (PE-conjugated donkey anti-guinea
pig F(ab’)2, Jackson ImmunoResearch Labs 706-116-148,
RRID AB_2340455, dilution 1:1000) was used to detect
MAP2b- and GFAP-labeled cells. AlexaFluo-488 goat
anti-mouse F(ab’)2 antibody was used to detect FcγRII
(CD32)-labeled cells (Jackson ImmunoResearch Labs 115-
546-006, RRID AB_2338860, dilution 1:1000), while Alex-
aFluor 647 goat anti-rabbit IgG (H+L) was used to detect
FcγRI (CD64)-labeled cells (Thermo Fisher Scientific A-
21245, RRID AB_2535813, dilution 1:1000). After incuba-
tion with secondary antibodies, the cells were washed
twice with PBS and kept at 4 °C until analysis. A subset of
cells were fixed and incubated without antibodies as a
Table 1 Rat Fcgr primer and probe sets
Assay IDa Gene Gene accession number Amplification efficiency
Rn.PT.53a.13499403 FcgrIa NM_001100836 0.97
Rn.PT.53a.37633364 FcgrIIa NM_053843 0.90
Rn.PT.53a.36530803 FcgrIIb NM_175756 0.80
Rn.PT.53a.8706390 FcgrIIIa NM_207603 0.79
Rn.PT.53a.35905066 Fcgrt NM_033351 0.86
Rn.PT.42.8715862 Pgk1 NM_053291 0.86
Pgk1 was used as a reference gene
aAll primers and probes were obtained from Integrated DNA Technologies (IDT)
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negative control. Additional controls included cells incu-
bated with one primary antibody at a time, and cells incu-
bated only with secondary antibodies alone and in
combination, in order to set the maximum threshold for
non-specific binding. A FACS Calibur (BD Biosciences)
instrument was used for acquisition and compensation at
the UC Davis Flow Cytometry Shared Resource. Compen-
sation was performed using the data from cells incubated
with each of the cellular markers individually. Data were
analyzed and plotted using FlowJo V10 (RRID
SCR_008520, FlowJo, LLC, Ashland, OR).
Immunocytochemistry
For cell surface staining, cortical and hippocampal cell
cultures were grown on glass coverslips (5–9 × 104 cells/
cm2) and fixed on DIV 7 in 4% PFA for 20 min at room
temperature. Cells were blocked with PBS containing 1%
BSA and 10% goat normal serum (Vector Laboratories)
for 1 h at room temperature. After blocking, cultures were
stained with primary antibodies specific for FcγRI (rabbit
polyclonal anti-CD64, Santa Cruz Biotechnology sc-
15364, RRID AB_2103451, 2 μg/ml) or FcγRII (mouse
anti-rat CD32, BD Biosciences 550271, RRID AB_393568,
2 μg/ml) in PBS with 2% FBS overnight at room
temperature. Cultures were then rinsed with PBS, perme-
abilized with 0.25% Triton X-100 in PBS for 5 min and
stained with antibodies specific for GFAP (guinea pig
polyclonal anti-GFAP, Synaptic Systems 173 004, RRID
AB_10641162, dilution 1:1000) and MAP2b (guinea pig
polyclonal anti-MAP2b, Synaptic Systems 188 004, RRID
AB_2138181, dilution 1:1000) for 1 h at room
temperature. After incubation with primary antibodies,
cultures were rinsed 3 times with PBS and then incubated
with secondary antibodies (AlexaFluor-568 goat anti-
guinea pig IgG, Thermo Fisher Scientific A-11075, RRID
AB_141954; AlexaFluor-647 goat anti-rabbit IgG, Thermo
Fisher Scientific A-21245, RRID AB_2535813; and
AlexaFluor-488 goat anti-mouse F(ab’)2, Jackson Immu-
noResearch Labs 115-546-006, RRID AB_2338860, all di-
luted 1:1000) for 30 min. Cells were then rinsed twice
with PBS, quickly rinsed in water, and mounted on slides
in Prolong Gold Antifade with DAPI (Molecular Probes,
Thermo Fisher Scientific). Images were acquired using a
40× objective on the ImageXpress MicroXL high-content
screening system (Molecular Devices).
Proteotype analysis
Cell surface capture (CSC) technology was used as pre-
viously described [53] to identify the cell surface proteo-
type (e.g., surfaceome) in DIV 7, DIV 14, and DIV 21
hippocampal cell cultures (seeded at a density of 1 × 105
cells/cm2). Briefly, surface glycoproteins were gently oxi-
dized with 2 mM NaIO4 and subsequently biotinylated
with 5 mM biocytin hydrazide for 20 min. Cells were
harvested by scraping and lysed in lysis buffer (50 mM
ammonium bicarbonate, 0.25% Rapigest, 10 mM TCEP)
by sonication using a VialTweeter (Hielscher Ultrasonics
Gmbh, Germany). Proteins were alkylated for 30 min
with 10 mM iodoacetamide (room temperature in the
dark) and digested with trypsin overnight at 37 °C, in an
enzyme-to-protein ratio of 1:50. In order to inactivate
trypsin, samples were boiled 20 min and subsequently
incubated with 1 mM PMSF for 15 min at 37 °C while
shaking (300 rpm) and then acidified with 10% formic
acid to pH 3. Samples were centrifuged (10 min,
16,000 × g) before capturing biotinylated glycopeptides
using streptavidin affinity matrix (Pierce, Ultralink). Gly-
copeptides captured on the streptavidin affinity matrix
were washed as previously described and incubated with
PNGase F at 37 °C for 18 h to release N-glycosylated
peptides. Samples were acidified to pH 2–3 with formic
acid, and peptides were desalted with C18 UltraMicroS-
pin columns (The Nest Group) according to the manu-
facturer’s instruction and dried in a SpeedVac
concentrator (Thermo Scientific, Rockford, USA).
For mass spectrometric (MS) analysis, peptides were
reconstituted in 3% acetonitrile and 0.1% formic acid,
and separated by reverse-phase chromatography on a
high-pressure liquid chromatography (HPLC) column
(75-μm inner diameter; New Objective) packed in-house
with a 15-cm stationary phase (Magic C18AQ, 200 Å,
1.9; Michrom Bioresources) and connected to an EASY-
nLC 1000 instrument combined with an autosampler
(Proxeon). The HPLC was coupled to a Q Exactive plus
mass spectrometer equipped with a nanoelectrospray
ion source (Thermo Scientific). Peptides were loaded
onto the column with 100% buffer A (99% H2O, 0.1%
formic acid) and eluted at a constant flow rate of
300 nL/min for 30 min with a linear gradient from 6 to
20% buffer B (99.9% acetonitrile, 0.1% formic acid),
followed by 15 min from 20 to 35% buffer B and a wash-
ing step with 90% buffer B. Mass spectra were acquired
in a data-dependent manner (top 15). In a standard
method for medium-to-low abundant samples, high-
resolution MS1 spectra were acquired at 70,000 reso-
lution (automatic gain control target value 3 × 106) to
monitor peptide ions in the mass range of 375–1500 m/
z, followed by high-energy collisional dissociation
(HCD)-MS/MS scans @ 35,000 resolution (automatic
gain control target value 1 × 106). To avoid multiple
scans of dominant ions, the precursor ion masses of
scanned ions are dynamically excluded from MS/MS
analysis for 30 s. Single-charged ions and ions with un-
assigned charge states or charge states above 6 were ex-
cluded from MS/MS fragmentation.
For data analysis, SEQUEST software v27.0 was used
to search fragment ion spectra for a match to tryptic
peptides with maximally two missed cleavage sites from
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a protein database, which was composed of the Rattus
norvegicus reference proteome (Uniprot, organism ID
10116), various common contaminants and sequence-
reversed decoy proteins. The precursor ion mass toler-
ance was set to 20 ppm. Carbamidomethylation was set
as a fixed modification on all cysteines. The PeptidePro-
phet and the ProteinProphet tools of the trans-
proteomic pipeline (TPP v4.6.2) were used for the prob-
ability scoring of peptide spectrum matches, and infer-
ring protein identifications were filtered to reach an
estimated false-discovery rate of ≤ 1%. Finally, proteins
were filtered for cell surface glycoproteins as previously
described [53]. In brief, each identified protein was re-
quired to be identified with at least one peptide contain-
ing the consensus NXS/T glycosylation motif containing
an asparagine to aspartic acid deamidation site with a
MS measured mass difference of 0.986 Da, indicating
the cell surface labeling and the enzymatic deamidation
during the CSC workflow.
Cross-linking studies with IgG immune complex (IgG-IC)
To form an antibody-antigen immune complex, normal
mouse IgG and affinity-purified rat anti-mouse IgG with
minimal cross-reactivity to rat serum proteins were used
as previously described [54]. The mouse IgG was dialyzed
overnight against sterile PBS using a 10,000 Da molecular
weight cutoff Slide-A-Lyzer MINI dialysis device (Thermo
Fisher Scientific) to remove sodium azide. The dialysate
was spin-concentrated using Amicon ultra centrifugal fil-
ter units (Millipore) before complexing. The IgG-IC was
prepared fresh before each experiment by incubating
mouse IgG with rat anti-mouse IgG in a 1:1 ratio (w/w)
for 1 h at room temperature prior to addition to the cells,
with the exception of the internalization studies, where in-
cubation of cultures with each component of the immune
complex (AlexaFluor 647-labeled rat anti-mouse IgG,
Jackson ImmunoResearch Labs 415-605-166, RRID
AB_2340285; and normal mouse IgG, Santa Cruz Biotech-
nology sc-2025, RRID AB_737182, concentration ratio
1:1) was performed sequentially. Cultures treated with the
individual components of the IgG-IC were used as
controls.
Calcium imaging
To measure intracellular calcium concentration ([Ca2+]i),
dissociated hippocampal neurons were seeded at a density
of 1.5–3.0 × 104 cells/cm2 (1–3 wells per condition in 4 in-
dependent dissections) and cultured on Costar 96-well
plates (Corning). On DIV 7, cells were loaded with the
Ca2+-sensitive dye, Fluo-4 AM (2 μM; Thermo Fisher Sci-
entific), in imaging buffer (10 mM HEPES 140, pH 7.4,
mM NaCl, 5 mM KCl, 2 mM MgCl2, 2 mM CaCl2, and
10 mM glucose) for 30 min in a 5% CO2 humidified incu-
bator. Cultures were then washed with imaging buffer and
transferred onto the stage of the ImageXpress MicroXL
high-content imaging system. IgG-IC was applied to the
cells, and full-frame FITC images were captured in one
randomly chosen field per treatment (2 frames/s for 2.0–
2.2 min) using MetaXpress software (Molecular Devices).
Image capture was initiated at t = 0 s; a half volume of
IgG-IC or of a rat anti-mouse IgG control or a mouse IgG
control was added to an equal volume of imaging media
at t = 10 s (20th frame); KCl (50 mM) was added at the
end of each experiment (t = 110 s) to verify cell viability. A
total of 240–260 images were acquired per well, and 1–3
wells were used per treatment in cultures from 4 inde-
pendent dissections. Images were acquired in sequential
mode between individual wells so that each well would re-
ceive the respective treatment (vehicle or IgG-IC) and im-
ages would be acquired from that well before proceeding
to treatment of the next well. In instances where more
than one well per condition were used, images from one
well per condition across conditions were acquired as a
first set, then the whole procedure was repeated for the
next set of wells, in order to minimize as much as possible
the influence of time between incremental exposures.
Microscope stage coordinates were recorded for each
chosen field.
To quantify [Ca2+]i, images were thresholded to re-
move background fluorescence and regions of interest
(ROIs) were drawn around the soma of each Fluo-4-
loaded cell. Fluorescence intensity values across all ac-
quired images per ROI were logged into Excel spread-
sheets (Microsoft Corporation). Custom Excel macros
were written to automate data analysis. Briefly, ROIs
with an area < 30 μm2 were excluded from analysis, and
fluorescence data (F) for each of the remaining ROIs
were normalized to its baseline fluorescence value (F0;
frames 1–20). Only cells in which addition of KCl re-
sulted in a spike in normalized fluorescence intensity
with amplitude greater than 10% were included in fur-
ther analyses. For each cell, the maximum fluorescence
following application of IgG IC (F; measured in arbitrary
fluorescence units) was normalized to the baseline fluor-
escence (F0) for that cell and expressed as (F − F0)/F0 or
ΔF/F0. Cells were considered responsive to treatment
when the peak change in fluorescence intensity (ΔF/F0)
after treatment was > 50% of baseline fluorescence. The
total number of IgG-IC-responsive cells in 1–3 wells for
each concentration of IgG-IC was divided by the total
number of cells in those wells to derive the percentage
of the cells responding. Data from IgG-exposed cells
were compared to data from cells exposed to an equal
volume of fresh imaging media.
Erk phosphorylation assays
DIV 7 hippocampal cell cultures were treated with fresh
culture media, IgG-IC at 10 or 100 μg/ml, or rat anti-
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mouse IgG at 10 or 100 μg/ml (1 culture per condition
in each of 3 independent dissections). Following 30 min
of exposure at 37 °C in a 5% CO2 humidified incubator,
cultures were lysed with ice-cold lysis buffer (as de-
scribed for western blotting). Protease and phosphatase
inhibitors (1X Halt Protease and Phosphatase Inhibitor
Cocktail; Thermo Fisher Scientific) were added to the
lysis buffer immediately before cell lysis. Protein concen-
tration was determined using the Pierce BCA Protein
Assay Kit (Thermo Fisher Scientific), and 30 μg of pro-
tein from each sample was separated using 7.5 or 10%
Mini-PROTEAN TGX precast gels (Bio-Rad), then
transferred to PVDF membrane. Membranes were
blocked with Odyssey Blocking Buffer (Licor Biotechnol-
ogy) for 30 min at room temperature and then incubated
overnight at 4 °C with primary antibodies against
phospho-Erk1/2 (Phospho Thr 202 & Tyr204/rabbit
monoclonal anti-phospho-p44/42 MAPK (Erk1/2), Cell
Signaling Technology 9106, RRID AB_331768, dilution
1:1000) diluted in blocking buffer with 0.1% Tween-20.
Antibodies against GAPDH were used as loading con-
trols. After washing in PBS supplemented with 0.1%
Tween-20, membranes were incubated with secondary
antibodies diluted in blocking buffer with 0.1% Tween-
20 and 0.01% SDS for 1 h at room temperature. After
extensive rinsing, membranes were scanned using the
Odyssey Infrared Imaging System (Licor Biotechnology).
Blots were then incubated with stripping buffer
(62.5 mM Tris-HCl, pH 6.8, with 2% SDS and 100 mM
β-mercaptoethanol) for 1 h at 37 °C and then imaged to
confirm the absence of bands. Stripped membranes were
immunoblotted for total (phosphorylated and non-
phosphorylated) Erk1/2 (Erk 1/2/mouse monoclonal
anti-p44/42 MAP kinase, Cell Signaling Technology
4696, RRID AB_390780, dilution 1:2000). Antibodies
against GAPDH (rabbit monoclonal anti-GAPDH, Cell
Signaling Technology 2118, RRID AB_561053, dilution
1:6000) were used as loading controls. Following incuba-
tion with secondary antibodies, membranes were
scanned using the Odyssey Infrared Imaging System
(Licor Biotechnology). Secondary antibodies used for
these experiments were IR700DX goat anti-mouse IgG
(Rockland 610-130-121, RRID AB_220121), IR700DX
goat anti-rabbit IgG (Rockland 611-130-122, RRID
AB_220148), IR800 goat anti-mouse IgG (Rockland 610-
132-121, RRID: AB220125) and IR800 goat anti-rabbit
IgG (Rockland 611-132-122, RRID AB_220152), all di-
luted 1:10000. Densitometry values of bands, immunore-
active with antibody against total Erk1/2
(phosphorylated and non-phosphorylated) or antibody
that specifically recognizes phosphorylated Erk, were
normalized to densitometry values for GADPH-
immunopositive bands in the same sample. Normalized
data for treated samples were expressed as a percentage
of normalized data for vehicle controls from the same
experiment. As a positive control, lysates were collected
from peritoneal macrophages (one culture per condition
in a single experiment) exposed to 10 or 100 μg/ml IgG-
IC for 5 min at 37 °C in a 5% CO2 humidified incubator.
Internalization of immune complex in endosomes
To test whether binding of an immune complex (Alexa-
Fluor 647-labeled rat anti-mouse IgG and normal mouse
IgG) to FcγR leads to internalization of FcγR into endo-
somes, AlexaFluor 488-conjugated rat transferrin (Jack-
son ImmunoResearch Labs 012-540-050, RRID
AB_2337161) was used to label the entire endocytic re-
cycling pathway [55]. Briefly, hippocampal cell cultures
(seeded at a density of 5 × 104 cells/cm2) were exposed
on DIV 7 to fresh growth media or 100 μg/ml of rat
anti-mouse IgG for 10 min, followed by incubation with
a mixture of 100 μg/ml of normal mouse IgG and 30 μg/
ml labeled transferrin for 10 min. Incubations were per-
formed at 37 °C in a 5% CO2 humidified incubator.
Negative controls were incubated with rat anti-mouse
IgG and transferrin, but without normal mouse IgG. In a
subset of experiments, cultures were pre-incubated for
5 min with anti-FcγRI (Santa Cruz Biotechnology sc-
15364, RRID AB_2103451) or anti-FcγRIIb (BD Biosci-
ences 550271, RRID AB_393568) antibodies (at 10 μg/ml
each) to block the FcγR.
Following the 10-min transferrin exposure, cells were
fixed with 4% PFA. Images were acquired at × 40 magni-
fication using the ImageXpress MicroXL high-content
imaging system. Twenty-five sites were imaged per well
in two wells per condition in each of 3 (without Fc
block) or 5 (with Fc block) independent dissections. Im-
ages were analyzed using MetaXpress software. A cus-
tom data analysis module was created using Custom
Module Editor to calculate the average number of rat
anti-mouse fluorescent puncta co-localized with trans-
ferrin per cell.
Statistical analysis
Graphs were constructed in Graphpad Prism (RRID
SCR_002798; v5.01), and statistical analyses were per-
formed using SPSS (RRID SCR_002865; version 22.0.0.1)
unless otherwise specified. Statistical comparisons were
performed using block design ANOVA (experimental
days were used as blocks; a Tukey’s honest significant
difference/HSD test was used to identify significant dif-
ferences between groups) with the following exceptions:
(i) comparisons of Fcgr transcript levels between hippo-
campal and cortical cell cultures and data from the
transferrin endocytosis assays were analyzed by t test in
Graphpad Prism; (ii) assessment of fold-change in FcgR
mRNA expression post-exposure to IFNγ and of change
in FcgR transcript expression in vivo were performed by
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built-in randomization algorithms in REST 2009 (separ-
ately for each litter), then fold-changes and 95% confi-
dence intervals from each litter were copied into
Graphpad Prism to calculate p values; and (iii) densito-
metric analysis of constitutive FcγR expression in
cortical cells was performed in Graphpad Prism using
two-way ANOVA.
Results
In vivo and in vitro expression of FcγR transcripts in the
developing rat brain
We first examined the transcript profile of FcγR in the
developing rat brain. FcgrIa, FcgrIIa, FcgrIIb, FcgrIIIa,
and Fcgrt mRNA was quantified in the cortex, hippo-
campus, and cerebellum of P1 male and female pups
using qPCR. The spleen and liver from these pups were
used as control tissues. All five Fcgr transcripts were de-
tected in all three brain regions and control tissues in
both sexes (Fig. 1a). Significant differences in transcript
levels between males and females were not detected by
2-way ANOVA (testing for sex and tissue effects; p set
at 0.05) in any of the tissues examined; therefore, data
from both sexes were pooled for this and all subsequent
analyses. Significant differences were observed between
different FcgR transcript levels within each of the differ-
ent tissues (F(1,4)=116.880, p = 0.000 for spleen, F(1,4)=
103.749, p = 0.000 for liver, F(1,4) = 54.082, p = 0.000 for
cortex, F(1,4)=57.298, p = 0.000 for hippocampus,
F(1,4)= 74.946, p = 0.000 for cerebellum), and Fcgrt was
the most abundant transcript across all tissues and brain
regions tested (p = 0.000; block design ANOVA with
Tukey’s post hoc test; n = 6 pups from each of 2 inde-
pendent litters). Transcript levels for each FcgR differed
between tissues (F(1,4) = 52.436, p = 0.000 for FcgRIa,
F(1,4) = 132.459, p = 0.000 for FcgRIIa, F(1,4) = 161.012,
p = 0.000 for FcgRIIb, F(1,4) = 72.733, p = 0.000 for
FcgRIIIa, F(1,4) = 254.119, p = 0.000 for FcgRt; block de-
sign ANOVA). All Fcgr transcripts were expressed at
lower levels in the cortex, hippocampus, and cerebellum
compared to the spleen (p = 0.000; Tukey’s HSD post
hoc test). Fcgr levels also differed between brain regions.
Specifically, the cortex expressed less FcgrIIa (p = 0.006)
and FcgrIIb (p = 0.000) compared to the hippocampus,
and cortical levels of Fcgrt were lower than in the hippo-
campus (p = 0.000) or cerebellum (p = 0.001). FcgrIIb was
less abundant in the cerebellum than in the hippocam-
pus (p = 0.000). No differences in FcgrIa or FcgrIIIa
expression were observed between brain regions.
To assess whether Fcgr transcript levels changed as a
function of age, Fcgr transcript levels in tissues from P7
pups (n = 11 pups from two litters, except for the spleen
where n = 8 from two litters) were compared to levels
quantified in P1 tissues (n = 12 pups from two litters).
Fcgr transcript levels were generally increased in the
brain of P7 pups relative to their P1 littermates
(Additional file 1). Significant changes were observed in
the cerebellum where FcgrIIb (2.661 fold; 95% CI, 0.513–
23.645; p = 0.004) and Fcgrt (2.294 fold; 95% CI, 0.679–
9.559; p = 0.001) increased from P1 to P7, and in the
cortex, where FcgrIIb (2.491 fold; 95% CI, 0.343–22.422;
p = 0.034) increased from P1 to P7. Larger confidence
intervals for FcgrIIb and Fcgrt in the cerebellum are due
to the variability in the Ct values obtained between dif-
ferent animals and could be due to regional differences
in FcγR expression between different areas of the cere-
bellum (although the entire cerebellum was removed
and stored in RNALater across all animals, the pieces
that were used for analysis were randomly chosen). In
contrast to the cerebellum and the cortex, in the spleen,
FcgrIa (0.276 fold; 95% CI, 0.034–8.977; p = 0.018),
FcgrIIa (0.244 fold; 95% CI, 0.077–3.074; p = 0.001), and
Fcgrt (0.452 fold; 95% CI, 0.130–3.412; p = 0.009)
decreased significantly from P1 to P7. Fcgr transcript
levels did not change significantly between P1 and P7 in
the hippocampus or liver. Results for liver and spleen
can be found in Additional file 2.
To determine whether FcgrIa, FcgrIIa, FcgrIIb, FcgrIIIa,
and Fcgrt transcripts are also expressed in the develop-
ing rat brain in vitro, and particularly in non-immune
cells, mRNA levels of these Fcgr genes were quantified
by qPCR in primary hippocampal and cortical cells dis-
sociated from P1 rats (pooled male and female brain re-
gions). These cultures were comprised of MAP2b-
positive neurons and GFAP-positive astrocytes and were
confirmed to be devoid of microglia and endothelial
cells, as determined by lack of immunolabeling for
CD68 and Iba-1 (microglial markers) and CD31 (endo-
thelial cell marker), and to contain < 1% CD11b immu-
nopositive cells (Additional files 3 and 4). Consistent
with in vivo expression patterns, on DIV 2, all five Fcgr
transcripts were detected in hippocampal (Fig. 1b) and
cortical cell cultures (Fig. 1c). There were significant dif-
ferences in expression levels between different Fcgr tran-
scripts in hippocampal cell cultures (F(1,4) = 12.379, p =
0.016, block design ANOVA; n = 3 cultures per group in
each of two dissections). As observed in vivo, Fcgrt was
expressed at significantly higher levels than either FcgrIa
(0.060; p = 0.034) or FcgrIIIa (0.079; p = 0.013) (Fig. 1b).
Small differences between transcript levels were also ob-
served in DIV 2 cortical cell cultures (Fig. 1c; F(1,4) =
14.087, p = 0.013, block design ANOVA), with Fcgrt and
FcgrIIa being more abundantly expressed than FcgrIIb
(mean difference: 0.070; p = 0.023 and 0.066; p = 0.028,
respectively) or FcgrIIIa (0.065; p = 0.029 and 0.061; p =
0.036, respectively). Comparison of each Fcgr transcript
between the two culture types (t test) revealed a signifi-
cant difference only for Fcgrt, which was slightly more
abundant in hippocampal cell cultures compared to
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cortical cell cultures (mean difference = 0.025; p = 0.026;
df = 2).
To further assess the ontogeny of Fcgr mRNA expres-
sion in vitro, Fcgr transcript levels were determined from
total RNA isolated from primary hippocampal and
cortical cell cultures on DIV 7, 14, and 21 and compared
to levels on DIV 2. Significant changes in Fcgr expression
as a function of DIV were observed in both culture types.
The relative expression values along with 95% confidence
intervals and p values for each gene in hippocampal and
cortical cell cultures are listed in Table 2 (pooled data
from 6 cultures derived from 2 independent dissections;
REST2009 software built-in statistical analysis). In hippo-
campal cell cultures, FcgrIa, FgcrIIa, FcgrIIb, and FcgrIIIa
Fig. 1 Fcgr are expressed in the developing rat brain and in primary neurons and astrocytes. A Gene expression in the developing brain at postnatal
day 1 (P1). Results are presented as the inverse Ct value of the target gene normalized to the inverse Ct value for the reference gene (Pgk1) in the
same sample. Data from two independent litters are presented as the mean ± SEM. Section sign indicates significantly lower compared to the spleen;
a: significantly lower compared to hippocampus; b: significantly lower compared to cerebellum (block design ANOVA with Tukey’s HSD post hoc test).
B, C In vitro gene expression in primary hippocampal (B) and cortical cell (C) cultures on the second day in vitro (DIV2). Data from two independent
dissections are presented as the mean ± SEM. Double dagger indicates significantly lower compared to Fcgrt; c: significantly lower compared to FcgrIIa,
as determined by block design ANOVA with Tukey’s HSD post hoc test
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transcript levels were decreased on DIV 7, 14, and 21
compared to DIV 2, while Fcgrt expression remained con-
stant across all DIV. In cortical cell cultures, FcgrIa,
FcgrIIa, FcgrIIb, and FcgrIIIa levels were lower on DIV 7
compared to DIV 2, while only FcgrIIa and FcgrIIIa levels
were reduced on DIV 14 and DIV 21 compared to DIV 2.
Fcgrt levels were significantly increased on DIV 14 but not
changed on DIV7 or DIV21 compared to DIV 2.
FcγRIa, FcγRIIb, and FcγRIIIa proteins are expressed in
neurons and astrocytes
Having confirmed that non-immune cells in the devel-
oping rat brain express Fcgr and that the transcript pro-
file of Fcgr in vitro resembles that in vivo, we next
determined whether FcγR are expressed at the protein
level in primary hippocampal and cortical cell cultures.
We first used western blotting to interrogate FcγR pro-
tein expression in rat cortical cell cultures. Commercially
available antibodies specific for FcγRIa (CD64; protein
product of FcgrIa), FcγRIIb (CD32; protein product of
FcgrIIb), FcγRIIIa (CD16; protein product of FcgrIIIa),
and FcRn (protein product of Fcgrt) were initially tested
against cell lysates of adult rat peritoneal macrophages
as a positive control. Bands immunoreactive for FcγRIa
and FcγRIIIa of the anticipated size (40–45 kDa) were
detected in peritoneal macrophage lysates (not shown).
In contrast, anti-FcγRIIb and anti-FcRn antibodies failed
to react with macrophage cell lysates, suggesting that
these antibodies are not suitable for western blotting.
Similarly, FcγRIa (Fig. 2a) and FcγRIIIa (Fig. 2b), but not
FcγRIIb or FcRn, were detected in cortical cell lysates
collected on DIV 2, 7, 14, and 21. Densitometric analysis
revealed no significant differences in FcγRIa or FcγRIIIa
protein levels in cortical cells on DIV 7, DIV 14, and
DIV 21 compared to DIV 2 (Fig. 2c, d; F(1,3) = 1.371, p
= 0.4008 for FcγRIa; F(1,3) = 0.6472, p = 0.6353 for
FcγRIIIa, 2-way ANOVA).
In immune cells, the responses triggered as a result of
immune complex recognition by FcγR can vary from cell
to cell depending on the ratio of excitatory to inhibitory
FcγR expressed on each cell [34, 35]. We hypothesized
that FcγR subtype expression at the protein level simi-
larly differs between individual neurons and/or astro-
cytes. Using flow cytometry of cells dissociated from the
neocortex of P0 rat pups (Fig. 3a), we confirmed that
cortical neurons, identified as MAP2b-immunopositive
cells (Fig. 3b), and astrocytes, identified as GFAP-
immunopositive cells (Fig. 3c), respectively, express
FcγRIa (Fig. 3d, g) and FcγRIIb (Fig. 3e, h). Although
some cortical neurons expressed either FcγRIa or
FcγRIIb, a subset of cortical neurons expressed FcγRIa
and FcγRIIb simultaneously at varying intensities
(Fig. 3f ). Similarly, a subset of cortical astrocytes was
immunopositive for both FcγRIa and FcγRIIb (Fig. 3i).
To assess the subcellular expression of FcγR in neu-
rons and astrocytes, we used immunocytochemistry to
label hippocampal and cortical cells at DIV 7. Results
confirmed our flow cytometry data, showing hippocam-
pal and cortical neurons and astrocytes immunopositive
for FcγRIa (Fig. 4) and for FcγRIIb (Fig. 5). Although
MAP2b-immunopositive neurons were consistently im-
munoreactive for FcγRIa and/or FcγRIIb, immunolabel-
ing of GFAP-immunopositive astrocytes for FcγR was
highly variable between and within cultures. Some
GFAP-immunopositive cells in our cultures did not react
with either FcγRIa or FcγRIIb antibodies. Confocal
Table 2 Changes in Fcgr expression on DIV 7, 14, and 21 relative to DIV 2
DIV 7 vs. DIV 2 DIV 14 vs. DIV 2 DIV 21 vs. DIV 2
Gene R.Exp. 95% CI p R.Exp. 95% CI p R.Exp. 95% CI p
Hippocampal cells
FcgrIa 0.084 0.016–0.620 0.002↓ 0.021 0.003–0.241 0.000↓ 0.036 0.005–1.432 0.002↓
FcgrIIa 0.275 0.088–1.005 0.002↓ 0.183 0.022–0.661 0.001↓ 0.240 0.048–2.567 0.013↓
FcgrIIb 0.427 0.117–2.224 0.045↓ 0.327 0.043–3.014 0.058 0.215 0.036–1.453 0.007↓
FcgrIIIa 0.112 0.011–1.043 0.007↓ 0.061 0.011–0.468 0.001↓ 0.064 0.011–0.906 0.001↓
Fcgrt 1.209 0.406–3.412 0.512 1.202 0.461–3.745 0.473 1.105 0.320–3.341 0.737
Cortical cells
FcgrIa 0.264 0.046–1.625 0.016↓ 0.110 0.007–9.227 0.080 0.051 0.003–9.892 0.074
FcgrIIa 0.392 0.080–1.059 0.005↓ 0.262 0.075–0.835 0.001↓ 0.093 0.034–0.259 0.002↓
FcgrIIb 0.386 0.106–1.077 0.010↓ 0.527 0.037–36.8 0.535 0.308 0.025–5.478 0.185
FcgrIIIa 0.293 0.063–1.359 0.009↓ 0.039 0.009–0.147 0.001↓ 0.008 0.002–0.024 0.001↓
Fcgrt 2.543 0.532–9.585 0.061 2.135 1.101–4.622 0.002↑ 0.991 0.491–2.124 0.967
Relative expression = (concentration of Fcgr gene)/(concentration of reference gene Pgk1) [48]. Wherever the change in expression between two DIVs is
statistically significant (p value < 0.05; as determined by built-in randomization techniques in REST 2009 analysis software), arrows represent direction of change in
expression (↑ up; ↓ down)
R. Exp. relative expression, CI confidence interval
Stamou et al. Journal of Neuroinflammation  (2018) 15:7 Page 10 of 23
microscopy confirmed that when cells were fixed and
permeabilized before FcγR staining, they revealed intra-
cellular (in some cases including intranuclear) staining
for FcγRIa and FcγRIIb in addition to surface staining
(not shown); this pattern of intracellular staining was
not observed in cells which were immunolabeled before
fixation. Intracellular immunolabeling for FcγR in fixed,
permeabilized cells could be explained by the presence
of intracellular pools of FcγR in neurons and astrocytes,
available for translocation to the cell membrane or, con-
versely, reflect internalized receptors. The presence of
neuronal surface receptors in intracellular pools [56, 57],
as well as the presence of intracellular pools of FcγR in
leukocytes [58], have been described before.
FcγRIIIa and FcRn immunoreactivities were not
detected by immunocytochemistry in hippocampal or cor-
tical cell cultures. Although cultures of adult rat peritoneal
cells were immunoreactive for FcRn (data not shown),
FcRn immunoreactivity was not observed in hippocampal
and cortical cultures. The absence of FcγRIIIa immuno-
staining and the presence of FcγRIIb immunostaining in
primary cortical and hippocampal neurons are in contrast
to our western blot data, suggesting that the anti-FcγRIIIa
and anti-FcγRIIb antibodies we used are not dual purpose
Fig. 2 Western blot analyses of FcγRIa and FcγRIIIa expression in cortical cell cultures. Representative blots showing FcγRIa (a) and FcγRIIIa (b) expression in
cortical cells on DIV 2, 7, 14, and 21. Each sample was also probed for either GAPDH (FcγRIa immunoblots) or βIII-tubulin (FcγRIIIa immunoblots) as loading
controls. MW molecular weight standards, N lysis buffer used as a negative control, P lysates from peritoneal macrophages used as a positive control.
Densitometric analyses showed no significant effects of culture age on FcγRIa (c) or FcγRIIIa (d) expression. For each sample, the optical density of the FcγR
immunopositive band was normalized to the optical density of the loading control. Data are presented as the fold-change (± SEM) in normalized optical
density for each DIV relative to DIV 2 which is represented as the horizontal dotted line in the graphs
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antibodies that would be suitable for both western blotting
and immunocytochemistry. This possibility was confirmed
by observations that the anti-FcγRIIb antibody detected
FcγRIIb immunoreactivity in peritoneal cells by immuno-
cytochemistry but not by western blotting (data not
shown).
To confirm surface expression of FcγR in cultures of neu-
rons and astrocytes as detected by immunocytochemistry,
we employed chemoproteomic cell surface capture (CSC)
technology [53]. CSC technology enables surfaceome ana-
lysis and phenotyping of cells without antibodies by using a
mass spectrometry-based strategy. Following selective cell
surface labeling using a biotinylated probe, formerly N-
glycosylated and cell surface-residing glycoproteins were
identified. A non-proteotypic glycopeptide derived from ei-
ther FcγRII or FcγRIII was identified in surfaceome
Fig. 3 Cortical cells express FcγRIα and/or FcγRIIb receptors on their surface. Rat cortical cells (a side-scatter (y) versus forward-scatter (x) plot)
were labeled for FcγRIa, FcγRIIb, and either MAP2b (b) or GFAP (c) (forward scatter (y) versus fluorescence intensity (x)). MAP2b-positive cells
express either FcγRIa (d), or FcγRIIb (e) or both FcγRIa and FcγRIΙb (f). GFAP-positive cells express either FcγRIa (g), or FcγRIIb (h) or both receptors
(i). Forward scatter (y) versus fluorescence intensity (x) were plotted for (d), (e), (g), and (h), whereas (f) and (i) were plotted as FcγRIIb (x) versus
FcγRIa (y) fluorescence. The mean frequency of cells labeled with the respective markers is indicated in the graphs
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preparations from hippocampal cell cultures at DIV 7, DIV
14, and DIV 21. Using the open source tool, Protter [59]
(Fig. 6), the identified glycopeptide (ATVNDSGEYR) was
shown to map to the extracellular domain of FcγRII (Uni-
prot ID Q63203; Fig. 6a) and FcγRIII (Uniprot ID P27645;
Fig. 6b). These data provide additional and independent
confirmation that the FcγR protein (FcγRII and/or FcγRIII)
is located on the cell surface in hippocampal neuron-glia
co-cultures.
Factors that modulate FcγR expression and signaling in
immune cells exert similar effects in primary hippocampal
and cortical cell cultures
IFNγ is an important inflammatory mediator produced
by T cells and natural killer (NK) cells [60] that regulates
FcγR expression in immune cells [61–64]. IFNγ has been
suggested to upregulate FcγR expression in adult rat
microglia at the protein level [65], but whether IFNγ al-
ters expression of Fcgr mRNA in other cell types of the
rodent brain is not known. To address this question,
DIV 2 rat cortical cell cultures were exposed to
recombinant rat IFNγ at 100 ng/ml, a concentration pre-
viously shown to influence signaling in cultured cortical
neurons without affecting cell viability [66]. As deter-
mined using the statistical analysis package in the
REST2009 software (that includes built-in
randomization algorithms) to assess qPCR data, a 24-h
exposure of cortical cell cultures to IFNγ significantly in-
creased levels of FcgrIa (4.271-fold; 95% CI 3.705–
4.837), FcgrIIa (1.351-fold; 95% CI 1.008–1.695), and
FcgrIIIa (6.525-fold; 95% CI 4.403–8.646) but decreased
levels of FcgrIIb (0.326-fold; 95% CI 0.201–0.451) and
Fcgrt (0.653-fold; 95% CI 0.455–0.850) relative to sister
cultures treated with vehicle (0.1% DMSO) (Fig. 7a).
After 48 h of exposure to IFNγ (Fig. 7b), expression of
FcgrIa (4.297-fold; 95% CI 2.247–6.348), FcgrIIa (1.723-
fold; 95% CI 1.397–2.049), and FcgrIIIa (5.624-fold; 95%
CI 4.444–6.803) remained significantly elevated, and
levels of Fcgrt (0.802-fold; 95% CI 0.614–0.990) were still
significantly decreased. Grubb’s test identified one of the
6 independent experiments as an outlier for FcgrIIb tran-
script levels after a 48-h exposure to IFN; with this
Fig. 4 Cultured hippocampal and cortical neurons and astrocytes express FcγRIa on DIV 7. a, b Representative fluorescence micrographs and
magnified inserts from DIV 7 cortical and hippocampal cell cultures immunolabeled for FcγRIa (magenta) and either MAP2b (a green) or GFAP (b
green). Nuclei are stained with Hoechst dye (blue). Arrows highlight co-labeling of cells with MAP2b or GFAP and FcγRIa. Arrowheads indicate
immunolabeling for FcgRIa but not for MAP2b nor for GFAP
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outlier removed, FcgRIIb transcript levels were con-
firmed to be significantly decreased, similarly to the 24 h
exposure to IFNγ (0.326-fold; 95% CI 0.2279–0.4245).
Cross-linking of FcγR in primary neuron-glia co-cultures
triggers downstream events observed following FcγR
cross-linking in immune cells
In myeloid and lymphoid cells, cross-linking of excitatory
FcγR, such as FcγRIa and FcγRIIIa, by IgG immune com-
plexes (IgG-IC) triggers a rapid increase in intracellular
calcium ([Ca2+]i) levels [32]. In contrast, mobilization of
intracellular calcium is not observed upon ligation of in-
hibitory FcγR, such as FcγRIIb [32]. It has been suggested
that IgG-mediated activation of FcγR increases [Ca2+]i in
peripheral neurons [67, 68]. We adapted a previously pub-
lished approach of bath application of IgG-IC to stimulate
[Ca2+]i in hippocampal cell cultures [54]. To obtain high-
quality images of individual cells and to distinguish be-
tween IgG-mediated effects on [Ca2+]i and spontaneous,
synchronized calcium oscillations normally occurring in
mature hippocampal neurons in culture [69, 70], calcium
imaging studies were performed on low density DIV 7
hippocampal cell cultures pre-loaded with the calcium in-
dicator dye Fluo4. IgG-IC consisting of pre-complexed
mouse IgG and rat anti-mouse IgG was added to the cul-
ture medium at varying concentrations.
Calcium traces of individual cells showed that under
the culture conditions used in these experiments,
neurons did not exhibit synchronized calcium oscilla-
tions (Fig. 8a). Analysis of calcium traces of individual
cells indicated that exposure to IgG-IC caused
concentration-dependent increases in [Ca2+]i (Fig. 8b, c).
Although the shape of calcium traces in IgG-IC respon-
sive cells varied between IgG-IC concentrations and be-
tween experiments for any experimental condition,
including vehicle, they generally exhibited one of two
general responses: (i) a spike in [Ca2+]i or (ii) a gradual
increase in [Ca2+]i (Fig. 8a). Quantification of the per-
centage of cells that responded to IgG-IC revealed that
median values increased in a concentration-dependent
manner up to 1 μg/ml (Fig. 8b). Calculation of the aver-
age area under the curve (AUC) for calcium traces
Fig. 5 Cultured hippocampal and cortical neurons and astrocytes express FcγRIIb on DIV 7. a, b Representative fluorescence micrographs and
magnified inserts from DIV 7 cortical and hippocampal cells immunolabeled for FcγRIIb (magenta) and either MAP2b (a green) or GFAP (b green).
Nuclei are stained with Hoechst dye (blue). Arrows highlight co-labeling of cells with MAP2b or GFAP and FcγRIIb. Arrowheads indicate immunolabeling
for FcgRIIb but not for MAP2b nor for GFAP
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revealed a concentration-dependent increase up to 1 μg/
ml IgG-IC (Fig. 8c), whereas a reduction in average AUC
was observed with 10 μg/ml IgG-IC and an increase was
observed with 100 μg/ml IgG-IG. However, no statistically
significant differences between means were found for ei-
ther endpoint (block design ANOVA with statistical sig-
nificance set at p = 0.05; n = 1–3 cultures in each of 4
independent dissections). The individual components of
the IgG-IC were used in control experiments. Specifically,
cells were incubated with either 100 μg/ml mouse IgG or
with 100 μg/ml rat anti-mouse IgG and the percentage of
responding cells as well as the average AUC of the calcium
traces were calculated (Fig. 8b, c). Both mouse IgG and rat
anti-mouse IgG at a very high concentration of 100 μg/ml
increased [Ca2+]i in some cells (Fig. 8b). The median AUC
for calcium traces in response to 100 μg/ml mouse IgG
was lower compared to 100 μg/ml IgG-IC, whereas the
median AUC of the calcium traces at 100 μg/ml rat anti-
mouse IgG was higher compared to 100 μg/ml IgG-IC
(Fig. 8c). However, these differences were not significantly
different from untreated cells, as determined by block de-
sign ANOVA (statistical significance set at p = 0.050; n =
1–3 cultures in each of 3 independent dissections for
mouse IgG alone and 2 independent dissections for rat
anti-mouse IgG alone). Although we did not test the indi-
vidual components of the IgG-IC at concentrations lower
than 100 μg/ml, based on evidence that IgG alone (in the
absence of immune complex) has been shown to act
Fig. 6 Cell surface capture proteomics identify FcγRIIb and FcγRIIIa
in rat hippocampal neurons and astrocytes. a, b Sequence coverage
of identified FcγR on topological prediction maps for rat FcγRIIb (a
Uniprot ID Q63203) and rat FcγRIIIa (b Uniprot ID P27645) were
generated using Protter (http://wlab.ethz.ch/protter). The sequence
of the identified peptide is depicted in blue
Fig. 7 Fcgr mRNA levels in rat cortical cells are modulated by IFNγ.
Effect of IFNγ (100 ng/ml) treatment for 24 h (a) or 48 h (b) on Fcgr
expression in DIV 2 cortical cell cultures. The fold-change in Fcgr
expression in IFNγ-treated cells relative to untreated cells (horizontal
dotted line along x-axis) is plotted as whisker box plots. The horizontal
line in each box represents the mean; lower and upper box limits, the
25th and 75th percentile, respectively; whiskers, the 1–99th percentile
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Fig. 8 IgG-immune complex (IC) concentration-dependently increases [Ca2+]i in primary hippocampal cells. DIV 7 hippocampal cell cultures were
loaded with calcium indicator dye Fluo-4 prior to experimental manipulation. IgG-IC or vehicle were added 10 s after recordings started, and KCl
(50 mM) was added at the end of each 2 min recording to verify cell viability. Changes in [Ca2+]i were calculated by measuring changes in fluorescence
intensity (ΔF/F0). a Randomly selected traces of [Ca2+]i in KCl-responsive cells exposed to varying concentrations of IgG-IC (1:1 ratio of pre-complexed
mouse IgG and rat anti-mouse IgG). b The percentage of cells that responded to IgG-IC or to the individual components of the immune complex (as
evidenced by an increase in fluorescence > 50% of baseline fluorescence). The total number of cells that responded to IgG-IC or to the individual
components of the immune complex (each at 100 μg/ml), divided by the total number of cells analyzed are provided in parentheses for each
experimental condition. No significant differences were observed between groups. c Mean change in [Ca2+]i as determined by the average area under
the curve (AUC) of the ΔF/F0 tracing for cells that responded to IgG-IC or to the individual components of the immune complex (each at 100 μg/ml).
No significant differences were observed between groups. Whisker box plots depict 25th–75th percentile range of values (box edges), median
(horizontal line in box), and 1st–99th percentile range of values (whiskers)
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antagonistically on FcγR signaling in immune signaling,
we would not expect to observe a robust calcium response
at lower concentrations of the individual components of
the immune complex [71, 72].
To exclude the possibility that these studies were con-
founded by varying percentage of astrocytes comprising
the total cell population, cultures from 2 of the 4 inde-
pendent dissections used for this study were
immunostained for MAP2b and GFAP following
completion of the calcium assay. Fluorescent images of
the same fields in the cells that had been used for the
calcium assay were acquired to compare calcium traces
from neurons versus astrocytes. Analysis of calcium
traces of neurons alone was conducted as above, and the
results (not shown) were similar to those reported above,
independent of cell type, e.g., the percentage of neurons
responsive to IgG-IC was concentration dependent, but
not significantly different from vehicle control.
In immune cells, increased [Ca2+]i as a result of cross-
linking of excitatory FcγR has been linked to activation
of the MAPK signaling pathway and Erk phosphoryl-
ation [32]. Similarly, we observed that IgG-IC increased
levels of phosphorylated Erk (pErk) in adult rat periton-
eal cells in a concentration-dependent manner (Fig. 9a).
The ratio of pErk to Erk was increased significantly
(60.44; p = 0.046; Tukey’s HSD) in DIV 7 hippocampal
cell cultures exposed to IgG-IC at 10 μg/ml relative to
control cultures treated with media alone but not at
100 μg/ml (Fig. 9b; (F(2,7) = 3.331, p = 0.026, block de-
sign ANOVA)). In contrast, when cells were exposed to
rat anti-mouse IgG alone, 10 μg/ml had no effect on Erk
phosphorylation whereas 100 μg/ml significantly in-
creased the pErk/Erk ratio (70.05; p = 0.016; Tukey’s
HSD) (Fig. 9b). Exposure to IFNγ (30 ng/ml) had no sig-
nificant effect on the pErk/Erk ratio in hippocampal cell
cultures, and IFNγ did not enhance the effect of IgG-IC
Fig. 9 IgG-immune complex (IgG-IC) increases Erk phosphorylation in primary hippocampal cell cultures. a Rat peritoneal macrophages were exposed
for 5 min to varying concentrations of IgG-IC, lysed, and immunoblotted for phosphorylated Erk (pErk). The optical density of pErk immunoreactive
bands, normalized to GAPDH, were 600-fold higher in peritoneal cells exposed to 10 μg/ml IgG-IC and > 10,000-fold higher in peritoneal cells exposed
to 100 μg/ml IgG-IC compared to cells exposed to media alone. b DIV 7 hippocampal cells were exposed for 30 min to 10 or 100 μg/ml IgG-IC (1:1
ratio of pre-complexed mouse IgG and rat anti-mouse IgG), or to 10 or 100 μg/ml rat anti-mouse IgG. Cell lysates were separated by SDS PAGE and
then immunoblotted for pErk, total Erk, and GAPDH. The optical density of bands immunoreactive for pErk and total Erk was normalized to the optical
density of GAPDH immunoreactive bands in the same sample. The ratio of pErk to Erk is plotted as a percentage of vehicle controls. Data are presented
as the mean ± SEM. MW molecular weight standards
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on this outcome after 30 min nor after 24 h of exposure
(Fig. 9b and Additional file 5).
In macrophages, cross-linking of FcγR by immune com-
plex often results in FcγR internalization into endosomes
[73]. To determine whether this also occurs in neural
cells, DIV 7 hippocampal cell cultures were “primed”
using rat anti-mouse IgG conjugated to AlexaFluor 647,
followed by addition of mouse IgG and AlexaFluor 488-
labeled rat transferrin, which labels the entire endosome
pathway [55]. Intracellular puncta dual-labeled for rat
anti-mouse IgG and transferrin (Fig. 10a, c) were quanti-
fied as a measure of FcγR internalization. The number of
puncta immunopositive for both rat anti-mouse IgG and
transferrin was significantly increased in cultures exposed
to the IgG-IC (p = 0.011; df = 5; mean difference = −0.7416
by t test of log transformed data), but not in cultures ex-
posed to rat anti-mouse IgG in the absence of mouse IgG
(Fig. 10b). This effect of IgG-IC was significantly reduced
in hippocampal cell cultures pre-incubated with anti-
bodies against FcγRIa (CD64) or FcγRIIb (CD32) (F =
5.92; p = 0.007; df = 28; Tukey’s HSD) (Fig. 10c, d).
Discussion
Emerging evidence suggests that FcγR are expressed by
neurons and macroglia in the adult human and murine
nervous system [7, 43]. However, available data are frag-
mented (see Additional file 6 which summarizes relevant
information available in published scientific literature),
and a comprehensive evaluation of FcγR expression and
function in the developing brain is lacking. This also holds
true for rat models of neurodevelopmental disease, despite
the recognized value of rats as a model species in neuro-
sciences and the increasing availability of novel genetic rat
models of neurodevelopmental disease [74]. The data re-
ported here address this gap by documenting in vivo ex-
pression of FcgRIa, FcgRIIa, FcgRIIb, FcgRIIIa, and Fcgrt
mRNA in the neonatal rat cortex, hippocampus, and cere-
bellum at levels comparable to those observed in the liver
and spleen. In vitro, expression of FcγRIa, FcγRIIb, and
FcγRIIIa was confirmed at the mRNA and the protein
level. In contrast, FcRn, which is encoded by Fcgrt, was
not detected in either hippocampal or cortical cultures
using either antibody-based or proteomic methods. A lack
Fig. 10 Exposure to IgG-immune complex (IC) triggers endocytosis of FcγR in rat hippocampal cells. a, b DIV 7 hippocampal cells were incubated with
rat anti-mouse IgG (magenta), followed by incubation with normal mouse IgG and transferrin (green) to label the entire endosomal pathway; nuclei are
stained blue (DAPI). c, d Cells were pre-incubated with either FcγRIIb or FcγRIa antibodies to block FcγR before incubation with rat anti-mouse IgG,
mouse IgG, and transferrin. a, c Representative photomicrographs of co-localization of rat anti-mouse IgG and transferrin (evident as white puncta). b, d
Quantification of dual-labeled puncta by t test of log-transformed data (b) or one-way ANOVA followed by Tukey’s post hoc test (d). Data are presented
as the mean ± SEM. Scale bar = 30 μm. Trsf = transferrin; IC = IgG immune complex
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of correlation between mRNA and protein levels in
biological samples is not unusual [75, 76], and to date,
there is no published evidence of FcRn protein expression
in neurons or astrocytes. However, it is possible that the
lack of immunoreactivity for FcRn in our cultures could
be due to technical limitations of the antibodies/mass
spectrometry analyses used. Collectively, our data provide
direct evidence that FcγRIa, FcγRIIb, and FcγRIIIa are
expressed by developing hippocampal and cortical neu-
rons and astrocytes, thereby proving that FcγR expression
in the CNS is not limited to resident immune cells.
Consistent with what is known about FcγR signaling
in immune cells [32, 77–79], we observed that IgG-IC
triggered increased [Ca2+]i, Erk phosphorylation, and in-
ternalization of immune complexes in primary rat
neuron-glia co-cultures. A potential confounding factor
in the interpretation of these experiments is that the rat
IgG used in the IgG-IC reacted with antigens other than
FcγR on the surface of neurons and astrocytes. However,
this possibility is not likely a significant issue because
the rat IgG we used in our studies was highly cross-
adsorbed against rat antigens. Moreover, antibodies
against FcγRIa or FcγRIIb blocked immune complex in-
ternalization in neurons, consistent with evidence that
both excitatory and inhibitory FcγR can internalize im-
mune complexes in immune cells [33, 80–82].
A canonical response to cross-linking of FcγR by IgG-IC
is increased [Ca2+]i. In primary hippocampal neurons ex-
posed to IgG-IC, two general calcium responses were ob-
served: a variable onset spike or a gradual rise in [Ca2+]i.
These variable calcium responses to FcγR cross-linking
are in contrast to the sharp calcium spikes reported in
dorsal root ganglion (DRG) neurons exposed to a similar
IgG-IC preparation [54]. The DRG calcium response re-
sembles the rapid [Ca2+]i spike typically observed in mac-
rophages stimulated with IgG-opsonized erythrocytes
[78]. However, the variable calcium responses observed in
hippocampal neurons are in agreement with the variability
of calcium responses in immune cells, which range from
isolated [Ca2+]i transients to long-lasting oscillations and
increased plateaus [83, 84]. These variable calcium
responses in immune cells are thought to be due to the
diversity of FcγR subtypes expressed on these cells [34, 35,
85, 86]. Thus, the considerable variability observed in the
calcium response of hippocampal cell cultures to IgG-IC
likely reflects differences in the relative expression of acti-
vating versus inhibitory FcγR isotypes within and between
cell types in our culture system, an interpretation that was
confirmed by our flow cytometry data (co-expression of
FcγRIa and FcγRIIb on the surface of neurons and astro-
cytes). Also consistent with this interpretation is that DRG
neurons, unlike hippocampal neurons, do not express
FcγRIIb or FcγRIIIa [54]. Interestingly, in primary hippo-
campal cell cultures, the individual components of the
IgG-IC (mouse IgG or rat anti-mouse IgG) also elicited in-
creased [Ca2+]i when added at very high concentrations
that are not physiologically relevant, suggesting that re-
sponsive cells in our cultures predominantly expressed the
high affinity FcγRIa. This is supported also by the in-
creased pErk/Erk ratio observed in response to the high
concentration (100 μg/ml) of rat anti-mouse IgG. On the
other hand, the lack of effect of exposure to the high con-
centration of IgG-IC on the pErk/Erk ratio, which was in
contrast to the variable increase in [Ca]i and the increased
co-localization with transferrin at this concentration, is
supported by evidence that [Ca]i mobilization and FcγR
internalization depend on the type and concentration of
the stimulus, and both can occur independent of Erk
phosphorylation [87–89]. Moreover, Erk activation in
neurons is also dependent on the concentration of the
stimulus [90]. These findings are further supported by evi-
dence that calcium transients in immune cells can be dif-
ferentially regulated by different FcγR [91] and that
different FcγR have different affinities for different IgG
isotypes. More sophisticated experiments with neurons
knocked-down for individual FcγR subtypes and exposed
to a low-to-high range of IgG-IC containing receptor-
specific IgG isotypes could further elucidate the complex
mechanisms likely underlying FcγR signaling in neurons
and astrocytes in the developing brain.
FcγR expression in immune cells is regulated by IFNγ.
Specifically, IFNγ upregulates FcγRIa expression [62,
92–94], stimulates FcγRIa function [92], and decreases
the expression of FcγRIIb and FcRn [95, 96]. Similarly,
we observed that IFNγ increased FcgrIa and decreased
FcgrIIb and Fcgrt in DIV 2 and DIV 3 cortical cell cul-
tures. We did not, however, see an effect of IFNγ on Erk
phosphorylation after stimulation with IFNγ for 30 min.
It has been reported that IFNγ upregulates macrophage
FcγRIa at the protein level after prolonged (> 1 h) but
not after short-term (30 min) stimulation [92]. However,
even stimulation with IFNγ for 24 h did not significantly
increase Erk phosphorylation in either hippocampal or
cortical cell cultures (Additional file 5). While we cannot
rule out the possibility that we did not sample at the
appropriate time after IFNγ stimulation to detect in-
creased Erk phosphorylation, our data do, nonetheless,
support the hypothesis that IFNγ signaling plays a role
in regulating Fcgr transcript expression in neurons and/
or astrocytes in the developing rat brain.
The functional significance of FcγR expression in hippo-
campal and cortical neurons and astrocytes remains to be
determined. Studies suggesting that FcγR trigger differen-
tiation of oligodendrocyte precursor cells and are critical
for normal development and function of Purkinje cells
support a role for FcγR expressed on non-immune cells in
CNS development [12, 13]. In support of this hypothesis,
FcγRIa expression has been previously reported in human
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infant neocortical pyramidal neurons [97]. Conversely,
FcγR may be involved in adverse neurodevelopmental out-
comes [20–26], as suggested by evidence that inflamma-
tion can have detrimental effects in fetal brain
development [98–102]. Recent evidence of a functional
role for FcγR-bearing cells in antibody-dependent en-
hancement of Zika virus infection suggests a potentially
critical role of FcγR expression on developing neurons
and astrocytes in neurodevelopmental deficits resulting
from infection [103, 104]. Alternatively, FcγR-mediated
endocytosis of antibodies attached to viruses can also be
part of a protective mechanism, as it is has been shown to
be the first step in a TRIM21-mediated intracellular im-
mune response which disables the virus in the cytosol [15,
105].
Considering the complexity of FcγR signaling that
arises from the multiplicity of receptor subtypes/func-
tions, their differing affinity for specific IgG subclasses,
and their expression by multiple cell types, our novel
data demonstrating developmental expression of func-
tional FcγR by neurons and astrocytes and the regulation
of their expression by classic immune molecules under-
score the need for further characterization of the role of
FcγR during normal and pathogenic neurodevelopment.
Conclusions
The data reported herein constitute the first comprehen-
sive investigation of FcγR expression and signaling on
neurons and astrocytes of the developing rat brain. Our
findings show that neurons and astrocytes in the devel-
oping brain express FcγR and that cross-linking of FcγR
by IgG immune complexes activates downstream events
in these non-immune cells, similar to events following
FcγR activation in immune cells, including intracellular
signaling and internalization of the antibody-receptor
complex. These observations suggest a novel mechanism
to explain the reported association between maternal
antibodies that target antigens in the developing brain
with increased risk for having a child diagnosed with a
neurodevelopmental disorder.
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